|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Combining chemotherapy and targeted therapies in metastatic colorectal cancer显示文摘Colorectal cancer remains one of the major causes of cancer death worldwide. During the past years, the development of new effective treatment options has led to a considerable improvement in the outcome of this disease. The advent of agents such as capecitabine, irinotecan, oxaliplatin, cetuximab and bevacizumab has translated into median survival times in the range of 2 years. Intense efforts have focused on identifying novel agents targeting specific growth factor receptors, critical signal transduction pathways or mediators of angiogenesis. In addition, several clinical trials have suggested that some of these molecularly targeted drugs can be safely and effectively used in combination with conventional chemotherapy. In this article we review various treatment options combining cytotoxic and targeted therapies currently available for patients with metastatic colorectal cancer. | J Rodriguez R Zarate E Bandres A Viudez A Chopitea J García-Foncillas I Gil-Bazo | 2007 | World Journal of Gastroenterology2007，13，44： | 1 |
| 2 | Prognostic factors and prevention of radioembolization‐induced liver disease显示文摘 | Belen Gil‐Alzugaray Ana Chopitea Mercedes I?arrairaegui Jose I. Bilbao Macarena Rodriguez‐Fraile Javier Rodriguez Alberto Benito Inés Dominguez Delia D’Avola Jose I. Herrero Jorge Quiroga Jesus Prieto Bruno Sangro | 2013 | Hepatology2013，，： | 1 |
| 3 | Epidermal growth factor receptor inhibitors in colorectal cancer treatment: What's new?显示文摘Colorectal cancer constitutes one of the most common malignancies and the second leading cause of death from cancer in the western world representing one million new cases and half a million deaths annually worldwide. The treatment of patients with metastatic colon cancer comprises different regimens of chemotherapeutic compounds (fluoropyrimidines, irinotecan and oxaliplatin) and new targeted therapies. Interestingly, most recent trials that attempt to expose patients to all five-drug classes (fluoropyrimidines, irinotecan, oxaliplatin, bevacizumab and cetuximab) achieve an overall survival well over 2 years. In this review we will focus on the main epidermal growth factor receptor inhibitors demonstrating clinical benefit for colorectal cancer mainly cetuximab, panitumumab, erlotinib and gefitinib. We will also describe briefly the molecular steps that lie beneath them and the different clinical or molecular mechanisms that are reported for resistance and response. | M Ponz-Sarvisé J Rodríguez A Viudez A Chopitea A Calvo J García-Foncillas I Gil-Bazo | 2007 | World Journal of Gastroenterology2007，13，44： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员